PMLiVE12 分钟
Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu
Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous ...